Biocon Sdn Bhd. (Biocon Malaysia) has set up Asia’s largest integrated insulins manufacturing facility at the Biotech Park in Johor, Malaysia with an investment of about USD 275 million, which is the highest foreign investment in Malaysia’s biotech sector till date. Biocon Malaysia is the first overseas biopharma manufacturing and research facility of Biocon Ltd., Asia’s premier biopharmaceuticals company and employs a team of nearly 600 professionals at this state-of-the-art facility.
Biocon is working to address the large global unmet need for high quality, affordable biosimilar insulins that provide cost-effective alternatives to existing therapies. The company has given patients, physicians and payers a wider option of treatment choices, enhanced patient access to insulin and improved diabetes management. In doing so, Biocon has emerged among the Top 3 biosimilar players globally for insulins.
- Company: Biocon Sdn Bhd
- Address: Jalan Bioteknologi 1, Kawasan Perindustrian SiLC, 79200 Iskandar Puteri, Johor, Malaysia
- Phone: +60 7560 0000 / +60 7560 0001 / +60 7560 0002
- Fax: +60 7560 0089
- Email: [email protected] / [email protected] / [email protected]
- Website: biocon.com
Products: Biosimilars, Small Molecules, Branded Formualations